Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Jumonji Domain-Containing Protein 2E (JMJD2E), also known as Lysine Demethylase 4E (KDM4E), is a histone demethylase that belongs to the JmjC domain-containing protein family. It catalyzes the demethylation of histone H3 at lysine 9 (H3K9), removing both di-methyl and tri-methyl groups. JMJD2E plays a role in epigenetic regulation, influencing gene expression by modifying chromatin structure. It is involved in processes such as embryonic stem cell pluripotency and differentiation, making it a potential target for therapeutic intervention, particularly in cancer.
Inhibits histone demethylation, specifically H3K9me2 and H3K9me3
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Jumonji Domain-Containing Protein 2E (JMJD2E).